ABSTRACT
Rationale Fibrosing interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), have heterogeneous postdiagnosis courses. Prognostic tools often rely on pulmonary function testing, imaging, or laboratory data that may not be uniformly available, and rarely provide individualized, time-updated forecasts of multiple trajectory events.
Objectives Can longitudinal healthcare claims generate test-free, time-updated forecasts of clinically actionable postdiagnosis trajectory events in patients with fibrosing ILD and IPF?
Methods Using de-identified longitudinal administrative claims from the Merative™ MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases, we constructed code-based digital twins (ZeBRA) encoding each patient’s evolving diagnosis, pharmacy, and procedure history. Horizon-specific models forecast seven claims-observable events: supplemental oxygen escalation, pulmonary hypertension, acute respiratory failure/ARDS composite, nausea, diarrhea, liver injury, and gastrointestinal bleeding. The analytic cohort included 345,918 patients with fibrosing ILD, including 17,284 with IPF. Predictions were evaluated in a time-updated follow-up setting over 1-month, 6-month, and 1-year horizons.
Results Predictive discrimination was consistent across events and horizons. In fibrosing ILD, AUC ranged from 0.691 for liver injury at 1 year to 0.912 for oxygen dependence at 1 month, with PPV ranging from 0.189 to 0.714. At 1 month, oxygen dependence achieved AUC 0.912 ± 0.005 with PPV 0.473 ± 0.005, and pulmonary hypertension achieved AUC 0.881 ± 0.005 with PPV 0.539 ± 0.005. The IPF subcohort showed analogous horizon-dependent performance, with AUC ranging from 0.687 to 0.855 and PPV from 0.245 to 0.817. At 1 month in IPF, PPV was 0.753 ± 0.015 for oxygen dependence and 0.817 ± 0.011 for pulmonary hypertension.
Conclusions A test-free digital-twin framework from routine longitudinal claims can provide individualized, time-updated forecasts of actionable fibrosing ILD and IPF trajectory events without imaging, pulmonary function tests, laboratory data, clinical notes, or patient-facing data collection. These forecasts may support low-burden reassessment, anticipatory care planning, and earlier recognition of elevated near-term risk for respiratory deterioration or management-altering complications.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used de-identified longitudinal administrative claims data from the Merative MarketScan Research Databases and conforms to Merative DUA stipulations. The University of Kentucky (UK) IRB approved use of the de-identified Merative MarketScan database for UK researchers using only Merative MarketScan data not linked with another database (IRB protocol 43542).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Institutional Review Board Approval This study used de-identified longitudinal administrative claims data from the Merative™ MarketScan® Research Databases, and conforms to Merative DUA stipulations. University of Kentucky (UK) IRB has approved use of the de-identified Merative MarketScan database for UK researchers using only Merative MarketScan data, not linked with another database (IRB protocol 43542).
Guarantor Statement Ishanu Chattopadhyay, PhD, takes responsibility for the content of the manuscript, including the integrity of the data analysis and the accuracy of the reported results.
Funding This project was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998 for computing resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, Merative, or any affiliated institutions. The sponsor had no role in the design or conduct of the study; or the decision to submit the manuscript for publication.
Financial/Nonfinancial Disclosures IC and DO are developers of the ZCoR framework. Intellectual property related to ZCoR-IPF is partially held by the University of Chicago and the University of Kentucky.
Use of AI Tools ChapGPT 5.5 was used in grammatical copy-editing. No AI tools were involved in analysis and research.
Data Availability
A functioning API implementation of the full ZeBRA pulmonary hypertension prediction pipeline, including model input processing and risk-score generation is available at https://github.com/zeroknowledgediscovery/ZeBRA_nhfild. Source data used for model training and validation consist of de-identified longitudinal administrative claims and are subject to data-use agreements with their respective data owners; these data cannot be publicly released. Derived summary statistics and scripts sufficient to reproduce the main analyses are available upon reasonable request.
